Inovio wins an $80.4 million judgment but warns collection may be limited
Inovio ($INO) announced a favorable judgment totaling approximately $80.4 million in its litigation against VGXI and GeneOne Life Science. The award comprises roughly $61.8 million in compensation and $18.7 million in legal fees and costs. The case concerned contractual obligations relating to DNA-plasmid supply and technology transfer. The Pennsylvania court ruled in Inovio’s favor on its claims and against the defendants’ counterclaims. The decision provides a potentially significant financial
0